Bruker (BRKR)
(Delayed Data from NSDQ)
$63.54 USD
-2.34 (-3.55%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $63.56 +0.02 (0.03%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$63.54 USD
-2.34 (-3.55%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $63.56 +0.02 (0.03%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Zacks News
Will Bruker (BRKR) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Bruker (BRKR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bruker's (BRKR) New Deal Widens Biopharma PAT Product Portfolio
by Zacks Equity Research
Bruker (BRKR) announces the acquisition of Tornado Spectral Systems Inc., a global provider of chemical analysis & measurement systems for Raman spectroscopy.
Bruker (BRKR) Expands Materials Science Research via New Deal
by Zacks Equity Research
Bruker (BRKR) announces the acquisition of the electron microscopy company Nion.
Here's Why Investors Should Retain Bruker (BRKR) Stock Now
by Zacks Equity Research
Investors remain optimistic about Bruker (BRKR) due to the strength of the BSI BioSpin and CALID groups.
Bruker (BRKR) Installs First 1.2 GHz NMR at Ohio University
by Zacks Equity Research
Bruker (BRKR) 1.2 GHz AVANCE NMR spectrometer is cutting-edge equipment capable of performing high-resolution liquid and solid-state NMR studies.
Accelerate Diagnostics (AXDX) Expands in In Vitro Diagnostics
by Zacks Equity Research
Accelerate Diagnostics' (AXDX) Arc system eliminates the need for overnight culture incubation, drastically reducing the wait time for identification results.
Bruker's (BRKR) New Collaboration to Use MALDI Biotyper System
by Zacks Equity Research
Bruker (BRKR) and Accelerate Diagnostics are set to work together to bring rapid, automated microbial identification directly from positive blood culture samples.
Pediatrix (MD) Q3 Earnings Miss on High Costs, Shares Down 12%
by Zacks Equity Research
Pediatrix's (MD) third-quarter results suffer from the decline in same-unit revenues attributable to patient volume. Management currently expects 2023 adjusted EBITDA to be within $200-$210 million.
Bruker (BRKR) Q3 Earnings and Revenues Top, '23 Sales View Up
by Zacks Equity Research
Bruker (BRKR) delivers better-than-expected earnings and revenues in the third quarter of 2023.
Bruker (BRKR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Bruker (BRKR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Bruker (BRKR) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Bruker (BRKR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why Investors Should Buy Bruker (BRKR) Stock Now
by Zacks Equity Research
The strong prospects of the BSI BioSpin and CALID group are likely to bode well for Bruker (BRKR) stock.
Bruker (BRKR) Becomes Majority Investor in MIRO Analytical AG
by Zacks Equity Research
Bruker's (BRKR) majority investment in MIRO adds state-of-the-art QCL technology to the Bruker Optics gas-analysis portfolio.
Bruker (BRKR) Introduces the New Hysitron TI 990 TriboIndenter
by Zacks Equity Research
Bruker's (BRKR) TI 990 is a comprehensive advancement of its industry-leading TriboIndenter platform.
Bruker (BRKR) Advances Novel 4D-Proteomics Capabilities
by Zacks Equity Research
Bruker's (BRKR) commitment to innovation and customer support makes it a great partner and helps achieve its mission of translating nature into medicine.
Bruker (BRKR) Inks Fraport Framework Contract for ETD Systems
by Zacks Equity Research
Bruker's (BRKR) DE-tector flex system uses a non-radioactive ionization source and is approved by national regulatory bodies and ECAC.
Here's Why You Should Retain Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Bruker (BRKR), backed by the performance of the CALID and NANO groups and strength in acquisitions.
Bruker (BRKR) Set to Acquire PhenomeX in an All-Cash Deal
by Zacks Equity Research
Bruker (BRKR) initiates its entry into since-cell biology research solutions with the acquisition of PhenomeX.
Bruker (BRKR) Q2 Earnings and Revenues Top, '23 Sales View Up
by Zacks Equity Research
Bruker (BRKR) delivers better-than-expected earnings and revenues in the second quarter of 2023.
Bruker (BRKR) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Bruker (BRKR) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Bruker (BRKR) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 4.17% and 5.54%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Waters (WAT) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Waters (WAT) delivered earnings and revenue surprises of 8.11% and 0.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Bruker (BRKR) based on the strong performances of the Bruker BioSpin Group.
Bruker (BRKR) Showcases UK Science Investments at EUROMAR 2023
by Zacks Equity Research
Bruker (BRKR) begins advanced life-science and green-tech research in the United Kingdom.
Bruker (BRKR) Launches the SciY Platform of Software Solutions
by Zacks Equity Research
Bruker's (BRKR) SciY platform provides many digital end-to-end solutions for life science research and development, manufacturing automation and QC.